Presenilins as therapeutic targets for the treatment of Alzheimer's disease
- 1 June 2001
- journal article
- review article
- Published by Elsevier in Trends in Molecular Medicine
- Vol. 7 (6) , 264-269
- https://doi.org/10.1016/s1471-4914(01)02064-0
Abstract
No abstract availableKeywords
This publication has 51 references indexed in Scilit:
- Structure of the Protease Domain of Memapsin 2 (β-Secretase) Complexed with InhibitorScience, 2000
- Cell‐free assays for γ‐secretase activityThe FASEB Journal, 2000
- Presenilin 1 Regulates Pharmacologically Distinct γ-Secretase ActivitiesJournal of Biological Chemistry, 2000
- Biochemical detection of Aβ isoforms: implications for pathogenesis, diagnosis, and treatment of Alzheimer’s diseaseBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2000
- The Role of Presenilin-1 in the γ-Secretase Cleavage of the Amyloid Precursor Protein of Alzheimer's DiseaseJournal of Biological Chemistry, 2000
- Lack of requirement for Presenilin1 in Notch1 signalingCurrent Biology, 1999
- Cell Surface Presenilin-1 Participates in the γ-Secretase-like Proteolysis of NotchJournal of Biological Chemistry, 1999
- Identification of a Novel Aspartic Protease (Asp 2) as β-SecretaseMolecular and Cellular Neuroscience, 1999
- γ-Secretase, Evidence for Multiple Proteolytic Activities and Influence of Membrane Positioning of Substrate on Generation of Amyloid β Peptides of Varying LengthJournal of Biological Chemistry, 1999
- The Presenilin 1 Protein Is a Component of a High Molecular Weight Intracellular Complex That Contains β-CateninJournal of Biological Chemistry, 1998